Greg Bannish received his PhD in immunology studying combined immunodeficiency, and performed postdoctoral studies at UPENN studying B cell receptor signaling. He then moved to Janssen (formerly Centocor), where he developed assays for immunological targets and improved hybridoma generation. Then he moved to Envigo for 11 years, developing a flow cytometry, cell culture, and immunology laboratory operating under GxP regulations, and later as Vice President, biopharmaceutical research, responsible for US biological drug programs. He then moved to Champions Oncology for 3 years to create, run, and support a regulatory flow cytometry laboratory. Recently, Greg has joined Flowmetric, Inc. as Senior Director of Laboratory Operations, where he is responsible to grow and support global flow cytometry operations.